Kent Kresa Concludes Tenure on MannKind Board; Steven Binder Set to Join

Kent Kresa, a seasoned member of the MannKind Corporation's Board of Directors, will be retiring from his role. The biopharmaceutical company, known for its focus on inhaled therapeutic products for endocrine and orphan lung diseases, announced this corporate governance development with an immediate effect. As Kresa steps down, Steven B. Binder is slated to take his place on the Board. Binder's appointment is expected to bring fresh perspectives to MannKind's strategic planning and operations. MannKind Corporation is headquartered in Westlake Village, California and trades under the stock ticker MNKD.

Impact on the Company

Kresa's retirement marks the end of a significant era for MannKind, as he has been instrumental in guiding the company through various phases of its growth and development. His leadership and insight have been invaluable to the organization. Looking ahead, MannKind believes that Binder's background and experience will prove to be a valuable asset for the company's continued progress and success.

About Steven B. Binder

Steven B. Binder brings a wealth of knowledge to the MannKind Board. His expertise in corporate finance and strategic initiatives will be leveraged to help steer the company towards its goals. The addition of Binder is anticipated to complement the existing board dynamic, enhancing MannKind's ability to navigate the complex landscape of the biopharmaceutical industry.

MannKind, Biopharmaceutical, Board